To be eligible for interferon alfa-2b treatment, chronic hepatitis B patients must be at least 1 year of age, HBsAg-positive for at least 6 months, and have elevated serum ALT levels and HBV replication as determined by the presence of HBeAg in serum. Other selection criteria include the presence of compensated liver disease and a liver biopsy that is consistent with chronic hepatitis B.

Suitable chronic hepatitis C patients are 18 years or older with compensated liver disease.



Early treatment increases success rates

The best treatment results with INTRON® A were obtained in circumstances that included the following patient factors:

• HCV genotype other than type I
• Low pretreatment HCV RNA levels
• Absence of cirrhosis
• Low hepatic iron concentration
• Younger age
• Short disease duration

To review clinical trial data and patient response information, see section, "INTRON® A Therapy."